Unlock instant, AI-driven research and patent intelligence for your innovation.

New use of co-stimulation factor and fusion protein

A fusion protein and application technology, applied in the direction of peptide/protein components, medical preparations containing active ingredients, drug combinations, etc., to achieve significant therapeutic activity

Active Publication Date: 2015-04-22
陕西金思铭生物技术有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there are no related reports on the use of co-stimulatory factor B7.1 and B7.1 fusion protein for the treatment of cervical cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New use of co-stimulation factor and fusion protein
  • New use of co-stimulation factor and fusion protein
  • New use of co-stimulation factor and fusion protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Preparation of B7.1-Fc in the present invention

[0029] The B7.1-Fc fusion protein was prepared by gene recombination technology. According to the method well known to those skilled in the biological field, the B7.1-Fc expression vector was obtained and constructed by PCR technology, and transferred to mouse myeloma NSO cells to screen to obtain long-term stable expression of the fusion protein B7 .1-Fc engineered cells, then through fed-batch culture to obtain high-expressing B7.1-Fc culture supernatant, and then purified by protein A affinity chromatography and ion exchange chromatography to obtain high-purity fusion protein, 4°C save.

[0030] The preparation method of B7.1-Fc in the present invention can refer to the preparation method in CN200580042109.0. The B7.1-Fc refers to B7.1 / IgG1Fc, that is, the fusion protein of B7.1 and IgG1Fc. See the sequence table Aihong Liu, Peisheng Hu; Clin Cancer Res 2005; 11(23) December 1, 2005, 8492-8502.

[0031] Determine...

Embodiment 2

[0032] Example 2 Pharmacodynamic experiment of immune costimulatory factor fusion protein B7.1-Fc

[0033] 1. Test sample and dose design

[0034] Name: Immune costimulatory factor fusion protein B7.1 / IgG1Fc (abbreviated as B7.1-Fc) was prepared according to Example 1

[0035] Provider: Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences

[0036] Properties: colorless, clear liquid

[0037] Storage conditions: 4℃ storage

[0038] Administration route: tail vein injection

[0039] Solvent: physiological saline

[0040] 2. Positive control:

[0041] Cyclophosphamide for Injection; Paclitaxel

[0042] 3. Tumor cell lines:

[0043] Mouse cervical cancer U14, mouse sarcoma S180, mouse melanoma B16-F10, all can be obtained by purchasing commercially available products

[0044] 4. Animals:

[0045] BALB / c mice, SPF / VAF grade provided by Beijing Huafukang Biotechnology Co., Ltd., certificate number SCXK (京)2009-0004

[0046] 5. Conditions of breeding facilities:

[0047] Barr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the use of B7.1 and B7.1 fusion protein in preparing a medicine for treating cervical cancer, sarcoma or melanoma. The immune co-stimulation factor fusion protein B7.1-Fc, particularly B7.1 / IgG1Fc, can effectively inhibit the growth of cervical cancer or sarcoma and particularly has obvious curative activity on cervical cancer; the therapeutical effect is equivalent to that of a positive medicine; and a new selection is provided for clinical medicine.

Description

Technical field [0001] The present invention relates to a new use of costimulatory factor B7.1 and B7.1 fusion protein. Background technique [0002] Cervical cancer is one of the common malignant tumors in women. It is caused by Human Papillomavirus (HPV). HPV virus can be transmitted directly through skin contact. It has an incubation period of more than ten years, so there are no symptoms at the beginning. Globally, approximately 500,000 women suffer from cervical malignant tumors and more than 250,000 die from cervical malignant tumors. In developing countries, cervical cancer is a common and frequent gynecological tumor, ranking first. Three months after the symptoms of cervical cancer appeared, two-thirds of the patients who came to the clinic had advanced cancer. Therefore, cervical tumors became the number one killer of girls’ lives. [0003] Although cervical tumors are the only cancer whose cause has been identified so far, their treatment is still consistent with gener...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/19A61K39/395A61P35/00
Inventor 雒蓬轶陈知航罗天学徐小萍陈春会曹路君杨伟彭红卫赵斌
Owner 陕西金思铭生物技术有限公司